PFKFB4 is significantly overexpressed in patients with late-stage carcinoma and predicts the progression of multiple tumors.[13] Moreover, FOXJ1 is upregulated in BC cells and increases cellular proliferation by enhancing glycolysis and is associated with poorer outcomes.[14] Nevertheless, predicting BC prognosis with a single gene is not as accurate as when a combination of biomarkers is used. This evidence concerns the gene FOXJ1 and breast cancer.